LZTS2 anticorps (C-Term)
Aperçu rapide pour LZTS2 anticorps (C-Term) (ABIN1450155)
Antigène
Voir toutes LZTS2 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- C-Term
-
Purification
- Affinity chromatography purified via peptide column
-
Immunogène
- A 17 amino acid synthetic peptide near the carboxy terminus of Human LZTS2
-
Isotype
- IgG
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 1.0 mg/mL
-
Buffer
- PBS containing 0.02 % Sodium Azide as preservative
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Conseil sur la manipulation
- Avoid repeated freezing and thawing.
-
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- LZTS2 (Leucine Zipper, Putative Tumor Suppressor 2 (LZTS2))
-
Autre désignation
- LZTS2
-
Sujet
- The leucine zipper putative tumor suppressor 2 (LZTS2, also known as LAPSER1), a member of the LZTS family, is a negative regulator of the Wnt signaling pathway. It represses beta-catenin-mediated transcriptional activation by promoting the nuclear exclusion of beta-catenin. LZTS2 is involved in cytokinesis and regulates katanin-mediated microtubule severing and release from the centrosome. LZTS2 may negatively regulate axonal outgrowth by preventing the formation of microtubule bundles that are necessary for transport within the elongating axon. LZTS2 is highly expressed in testis and prostate, but it is deleted in multiple cancers, including prostate tumors, suggesting that LZTS2 acts as a potential tumor suppressor.Synonyms: KIAA1813, LAPSER1, LZTS2, Leucine zipper putative tumor suppressor 2, hLZTS2
-
ID gène
- 84445
-
NCBI Accession
- NP_115805
Antigène
-